Mistletoe for cancer?
- 6 August 2003
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 107 (2) , 262-267
- https://doi.org/10.1002/ijc.11386
Abstract
Mistletoe extracts are widely used in the treatment of cancer. The results of clinical trials are however highly inconsistent. We therefore conducted a systematic review of all randomised clinical trials of this unconventional therapy. Eight databases were searched to identify all studies that met our inclusion/exclusion criteria. Data were independently validated and extracted by 2 authors and checked by the 3rd according to predefined criteria. Statistical pooling was not possible because of the heterogeneity of the primary studies. Therefore a narrative systematic review was conducted. Ten trials could be included. Most of the studies had considerable weaknesses in terms of study design, reporting or both. Some of the weaker studies implied benefits of mistletoe extracts, particularly in terms of quality of life. None of the methodologically stronger trials exhibited efficacy in terms of quality of life, survival or other outcome measures. Rigorous trials of mistletoe extracts fail to demonstrate efficacy of this therapy.Keywords
This publication has 14 references indexed in Scilit:
- Studien zur Misteltherapie - Eine aktuelle Übersicht mit Kurzfassungen der wichtigsten Studien 1996 - 2001 -Erfahrungsheilkunde, 2002
- Die Misteltherapie in der biologischen Tumorbegleitbehandlung1 - - im Spannungsfeld zwischen Erfahrung und Forschungsergebnissen -Erfahrungsheilkunde, 2002
- Mistletoe and survival time: too much room for biasFocus on Alternative and Complementary Therapies, 2001
- Mistletoe for cancer?European Journal Of Cancer, 2001
- The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patientsEuropean Journal Of Cancer, 2001
- Potentiation of Tumor Necrosis Factor-α-Induced Apoptosis by Mistletoe LectinImmunopharmacology and Immunotoxicology, 2000
- Adjuvant trial in melanoma patients comparing rIFN-α to rIFN-γ to Iscador to a control group after curative resection of high risk primary (≥3 MM) or regional lymphnode metastasis (EORTC 18871)European Journal Of Cancer, 1999
- Anwendung alternativmedizinischer Methoden durch onkologische PatientenDeutsche Medizinische Wochenschrift (1946), 1998
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Mistletoe treatment for cancer review of controlled trials in humansPhytomedicine, 1994